FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163393078> ?p ?o ?g. }

• W2163393078 endingPage "1677" @default.
• W2163393078 startingPage "1667" @default.
• W2163393078 abstract "Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1–21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomide–rituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1–21 in combination with different standard-dose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab–bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHL—relapsed/refractory disease, first-line, and maintenance—is presented here." @default.
• W2163393078 created "2016-06-24" @default.
• W2163393078 creator A5004152557 @default.
• W2163393078 creator A5025688165 @default.
• W2163393078 creator A5025865972 @default.
• W2163393078 creator A5044284041 @default.
• W2163393078 creator A5054623894 @default.
• W2163393078 creator A5058392949 @default.
• W2163393078 creator A5061713890 @default.
• W2163393078 creator A5066598802 @default.
• W2163393078 creator A5089882481 @default.
• W2163393078 date "2015-08-01" @default.
• W2163393078 modified "2023-10-15" @default.
• W2163393078 title "A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma" @default.
• W2163393078 cites W1489641321 @default.
• W2163393078 cites W1804392693 @default.
• W2163393078 cites W19039903 @default.
• W2163393078 cites W1970400561 @default.
• W2163393078 cites W1973532909 @default.
• W2163393078 cites W1974816429 @default.
• W2163393078 cites W1988805574 @default.
• W2163393078 cites W1990765152 @default.
• W2163393078 cites W1992059613 @default.
• W2163393078 cites W1992538067 @default.
• W2163393078 cites W1993598575 @default.
• W2163393078 cites W1994719395 @default.
• W2163393078 cites W1998217339 @default.
• W2163393078 cites W2000302977 @default.
• W2163393078 cites W2002433450 @default.
• W2163393078 cites W2004025546 @default.
• W2163393078 cites W2006713638 @default.
• W2163393078 cites W2017144533 @default.
• W2163393078 cites W2021954218 @default.
• W2163393078 cites W2025658051 @default.
• W2163393078 cites W2030646758 @default.
• W2163393078 cites W2048743906 @default.
• W2163393078 cites W2049869153 @default.
• W2163393078 cites W2056952913 @default.
• W2163393078 cites W2059492063 @default.
• W2163393078 cites W2066936999 @default.
• W2163393078 cites W2077848703 @default.
• W2163393078 cites W2078761761 @default.
• W2163393078 cites W2085346499 @default.
• W2163393078 cites W2095599841 @default.
• W2163393078 cites W2095669071 @default.
• W2163393078 cites W2096764404 @default.
• W2163393078 cites W2098002594 @default.
• W2163393078 cites W2099308699 @default.
• W2163393078 cites W2107071884 @default.
• W2163393078 cites W2111611512 @default.
• W2163393078 cites W2116194748 @default.
• W2163393078 cites W2120775216 @default.
• W2163393078 cites W2126772526 @default.
• W2163393078 cites W2135860817 @default.
• W2163393078 cites W2139751199 @default.
• W2163393078 cites W2139836848 @default.
• W2163393078 cites W2141053481 @default.
• W2163393078 cites W2148633649 @default.
• W2163393078 cites W2153558008 @default.
• W2163393078 cites W2157749844 @default.
• W2163393078 cites W2168450724 @default.
• W2163393078 cites W2169209759 @default.
• W2163393078 cites W2169598499 @default.
• W2163393078 cites W2169961966 @default.
• W2163393078 cites W2284979469 @default.
• W2163393078 cites W2461446459 @default.
• W2163393078 cites W2571698305 @default.
• W2163393078 cites W2577306999 @default.
• W2163393078 cites W2586225144 @default.
• W2163393078 cites W4248583329 @default.
• W2163393078 cites W88651028 @default.
• W2163393078 doi "https://doi.org/10.1093/annonc/mdv102" @default.
• W2163393078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25712458" @default.
• W2163393078 hasPublicationYear "2015" @default.
• W2163393078 type Work @default.
• W2163393078 sameAs 2163393078 @default.
• W2163393078 citedByCount "75" @default.
• W2163393078 countsByYear W21633930782015 @default.
• W2163393078 countsByYear W21633930782016 @default.
• W2163393078 countsByYear W21633930782017 @default.
• W2163393078 countsByYear W21633930782018 @default.
• W2163393078 countsByYear W21633930782019 @default.
• W2163393078 countsByYear W21633930782020 @default.
• W2163393078 countsByYear W21633930782021 @default.
• W2163393078 countsByYear W21633930782022 @default.
• W2163393078 countsByYear W21633930782023 @default.
• W2163393078 crossrefType "journal-article" @default.
• W2163393078 hasAuthorship W2163393078A5004152557 @default.
• W2163393078 hasAuthorship W2163393078A5025688165 @default.
• W2163393078 hasAuthorship W2163393078A5025865972 @default.
• W2163393078 hasAuthorship W2163393078A5044284041 @default.
• W2163393078 hasAuthorship W2163393078A5054623894 @default.
• W2163393078 hasAuthorship W2163393078A5058392949 @default.
• W2163393078 hasAuthorship W2163393078A5061713890 @default.
• W2163393078 hasAuthorship W2163393078A5066598802 @default.
• W2163393078 hasAuthorship W2163393078A5089882481 @default.
• W2163393078 hasBestOaLocation W21633930781 @default.
• W2163393078 hasConcept C126322002 @default.

• next